Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of REGN9035 and Vixticibart in Healthy and Hypertensive Subjects
NCT05291546Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2022
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in hypertension (HTN) comparing Part A: REGN9035 SAD with Part B: Vixticibart + REGN9035 (2 arms). Primary endpoint: Treatment Emergent Adverse Events. Started Apr 2022; status: completed.
02
Drugs
REGN5381imelciment
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05291546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05291546.